Kali-Extracts Files Patent Application for CBD Formulation to Treat COPD

Kali-Extracts-logo-CBD-CBDToday

DALLAS – Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today confirmed the company has filed a new patent application specifically on its formulation for symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions. The formulation for the treatment of symptoms associated with COPD and other similar respiratory conditions has been derived from the company’s existing patented cannabis extraction process. The company has also filed to register a trademark on the name RespRx as the brand name for its CBD formulation to treat the symptoms associated with COPD and other similar respiratory conditions. KALY plans to publish a website on Friday, August 23rd, dedicated to its new CBD formulation, RespRx, for treating symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions. The RespRx website to be published Friday will include details on KALY’s recent patent and trademark applications for the RespRx CBD formulation. The company first announced its RespRx CBD formulation yesterday in a comprehensive update on the company’s overall Biopharmaceutical Developments From Cannabis Extractions targeting over $170 billion treatment opportunities.

To learn more about the company visit https://www.kali-extracts.com/.

Advertisement
greentanktech.com